|
1
|
Cotrim AP and Baum BJ: Gene therapy: some
history, applications, problems and prospects. Toxicol Pathol.
36:97–103. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Verma IM and Somia N: Gene therapy –
promise, problems and prospects. Nature. 389:239–242. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee RH, Kim B, Choi I, et al:
Characterization and expression analysis of mesenchymal stem cells
from human bone marrow and adipose tissue. Cell Physiol Biochem.
14:311–324. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Erices A, Conget P and Minguell JJ:
Mesenchymal progenitor cells in human umbilical cord blood. Br J
Haematol. 109:235–242. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Le Blanc K, Rasmusson I, Sundberg B, et
al: Treatment of severe acute graft-versus-host disease with third
party haploidentical mesenchymal stem cells. Lancet. 363:1439–1441.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kidd S, Spaeth E, Dembinski JL, et al:
Direct evidence of mesenchymal stem cell tropism for tumor and
wounding microenvironments using in vivo bioluminescent imaging.
Stem Cells. 27:2614–2623. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Raper SE, Chirmule N, Lee FS, et al: Fatal
systemic inflammatory response syndrome in a ornithine
transcarbamylase deficient patient following adenoviral gene
transfer. Mol Genet Metab. 80:148–158. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Msaouel P, Iankov ID, Dispenzieri A and
Galanis E: Attenuated oncolytic measles virus strains as cancer
therapeutics. Curr Pharm Biotechnol. 13:1732–1741. 2012. View Article : Google Scholar :
|
|
9
|
Kucerova L, Altanerova V, Matuskova M,
Tyciakova S and Altaner C: Adipose tissue-derived human mesenchymal
stem cells mediated prodrug cancer gene therapy. Cancer Res.
67:6304–6313. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grisendi G, Bussolari R, Cafarelli L, et
al: Adipose-derived mesenchymal stem cells as stable source of
tumor necrosis factor-related apoptosis-inducing ligand delivery
for cancer therapy. Cancer Res. 70:3718–3729. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maddika S, Mendoza FJ, Hauff K, Zamzow CR,
Paranjothy T and Los M: Cancer- selective therapy of the future:
apoptin and its mechanism of action. Cancer Biol Ther. 5:10–19.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Backendorf C, Visser AE, de Boer AG, et
al: Apoptin: therapeutic potential of an early sensor of
carcinogenic transformation. Annu Rev Pharmacol Toxicol.
48:143–169. 2008. View Article : Google Scholar
|
|
13
|
Li X, Liu Y, Wen Z, et al: Potent
anti-tumor effects of a dual specific oncolytic adenovirus
expressing apoptin in vitro and in vitro. Mol Cancer. 9:102010.
View Article : Google Scholar
|
|
14
|
Schoop RA, Baatenburg de Jong RJ and
Noteborn MH: Apoptin induces apoptosis in an oral cancer mouse
model. Cancer Biol Ther. 7:1368–1373. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Torchilin VP and Lukyanov AN: Peptide and
protein drug delivery to and into tumors: challenges and solutions.
Drug Discov Today. 8:259–266. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Du J, Zhou L, Chen X, et al: IFN-γ-primed
human bone marrow mesenchymal stem cells induce tumor cell
apoptosis in vitro via tumor necrosis factor-related
apoptosis-inducing ligand. Int J Biochem Cell Biol. 44:1305–1314.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aboody KS, Najbauer J and Danks MK: Stem
and progenitor cell-mediated tumor selective gene therapy. Gene
Ther. 15:739–752. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun J, Yan Y, Wang XT, et al: PTD4-apoptin
protein therapy inhibits tumor growth in vivo. Int J Cancer.
124:2973–2981. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kyriakou CA, Yong KL, Benjamin R, et al:
Human mesenchymal stem cells (hMSCs) expressing truncated soluble
vascular endothelial growth factor receptor (tsFLk-1) following
lentiviral-mediated gene transfer inhibit growth of burkitt’s
lymphoma in a murine model. J Gene Med. 8:253–264. 2006. View Article : Google Scholar
|
|
20
|
Chang LJ and Gay EE: The molecular
genetics of lentiviral vectors - current and future perspectives.
Curr Gene Ther. 1:237–251. 2001. View Article : Google Scholar
|
|
21
|
Loebinger MR, Eddaoudi A, Davies D and
Janes SM: Mesenchymal stem cell delivery of TRAIL can eliminate
metastatic cancer. Cancer Res. 69:4134–4142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Danen-Van Oorschot AA, Zhang YH, Leliveld
SR, et al: Importance of nuclear localization of apoptin for
tumor-specific induction of apoptosis. J Biol Chem.
278:27729–27736. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Daugherty BL, Zavodny SM, Lenny AB, et al:
The uses of computer-aided signal peptide selection and polymerase
chain reaction in gene construction and expression of secreted
proteins. DNA Cell Biol. 9:453–459. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Flinterman M, Farzaneh F, Habib N, Malik
F, Gäken J and Tavassoli M: Delivery of therapeutic proteins as
secretable TAT fusion products. Mol Ther. 17:334–342. 2009.
View Article : Google Scholar
|
|
25
|
Danen-van Oorschot AA, van Der Eb AJ and
Noteborn MH: The chicken anemia virus-derived protein apoptin
requires activation of caspases for induction of apoptosis in human
tumor cells. J Virol. 74:7072–7078. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maddika S, Booy EP, Johar D, Gibson SB,
Ghavami S and Los M: Cancer-specific toxicity of apoptin is
independent of death receptors but involves the loss of
mitochondrial membrane potential and the release of mitochondrial
cell-death mediators by a Nur77-dependent pathway. J Cell Sci.
118:4485–4493. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu W, Xu W, Jiang R, et al: Mesenchymal
stem cells derived from bone marrow favor tumor cell growth in
vivo. Exp Mol Pathol. 80:267–274. 2006. View Article : Google Scholar
|
